首页> 外文期刊>British Journal of Clinical Pharmacology >Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects.
【24h】

Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects.

机译:紫锥菊和波多固醇与华法林在健康受试者中的药代动力学和药效学相互作用。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: This study investigated the pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. METHODS: This was an open-label, randomized, three-treatment, cross-over, clinical trial in healthy male subjects (n= 12) of known CYP2C9 and VKORC1 genotype who received a single oral dose of warfarin alone or after 2 weeks of pre-treatment with each herbal medicine at recommended doses. Pharmacodynamic (INR, platelet activity) and pharmacokinetic (warfarin enantiomer concentrations) end points were evaluated. RESULTS: The apparent clearance of (S)-warfarin (90% CI of ratio; 1.01, 1.18) was significantly higher during concomitant treatment with echinacea but this did not lead to a clinically significant change in INR (90% CI of AUC of INR; 0.91, 1.31). Policosanol did not significantly affect warfarin enantiomer pharmacokinetics or warfarin response. Neither echinacea nor policosanol had a significant effect on platelet aggregation after 2 weeks of pre-treatment with the respective herbal medicines. CONCLUSION: Echinacea significantly reduced plasma concentrations of S-warfarin. However, neither echinacea nor policosanol significantly affected warfarin pharmacodynamics, platelet aggregation or baseline clotting status in healthy subjects.
机译:目的:本研究调查了紫锥花和波多固醇与华法林在健康受试者中的药代动力学和药效动力学相互作用。方法:这是一项公开标记的,随机,三项治疗的,交叉的临床试验,针对已知CYP2C9和VKORC1基因型的健康男性受试者(n = 12),他们单独或单独服用华法林口服两次,服用华法林每种草药以推荐剂量进行预处理。评估了药效学(INR,血小板活性)和药代动力学(华法林对映体浓度)终点。结果:(S)-华法林的表观清除率(比率的90%; 1.01、1.18)在紫锥菊属药物的伴随治疗期间显着更高,但这并未导致INR发生临床上的显着变化(INR的AUC为90%CI) ; 0.91、1.31)。泊可醇没有显着影响华法林对映体的药代动力学或华法林反应。分别用中草药预处理2周后,紫锥菊和聚甲醛醇对血小板聚集均无明显影响。结论:紫锥菊显着降低了S-华法林的血浆浓度。然而,紫锥花和波利斯考索醇均未显着影响健康受试者中的华法林药效学,血小板聚集或基线凝血状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号